Skip to main content
Evidence Snapshot

TGF-beta receptor type-1

CHEMBL4439 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4439
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats TGF-beta receptor type-1 as ChEMBL target CHEMBL4439, mapped to UniProt P36897. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
TGF-beta receptor type-1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4439
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P36897
TGF-beta receptor type-1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why TGF-beta receptor type-1 matters

As of 2026-09-13

TGF-beta receptor type-1 is reviewed as TGF-beta receptor type-1 (UniProt P36897); TGF-beta receptor type-1 shows clinical signal disease relevance led by myelodysplastic syndrome. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 7 approved drugs, 3732 compounds, and 529 assays, with lead potency reaching pChEMBL 9.8.

Disease context
myelodysplastic syndrome

TGF-beta receptor type-1 shows clinical signal disease relevance led by myelodysplastic syndrome. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include GALUNISERTIB, VACTOSERTIB.

Start review with myelodysplastic syndrome because it currently carries clinical signal support. Linked drugs include GALUNISERTIB, VACTOSERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 3732 compounds, and 529 assays for this target. The dominant activity type is IC50. CHEMBL4209835 is the current potency anchor at pChEMBL 9.8.

Use CHEMBL4209835 as the tractability anchor when discussing potency (pChEMBL 9.8).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 9.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why TGF-beta receptor type-1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P36897, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why myelodysplastic syndrome is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3732
Total Compounds
529
Total Assays
7
Approved Drugs
IC50: 4072.0, KI: 64.0, EC50: 225.0, KD: 396.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4209835
 9.8 Ki —
No preferred name
CHEMBL4210246
 9.8 Ki —
No preferred name
CHEMBL4209583
 9.8 Ki —
No preferred name
CHEMBL5962152
 9.7 IC50 —
No preferred name
CHEMBL4217699
 9.7 Ki —

Approved Drugs

Structure Compound First Approval
MOMELOTINIB
CHEMBL1078178
 2023
CRIZOTINIB
CHEMBL601719
 2011
DASATINIB
CHEMBL5416410
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4439